# OnCo record duke-street-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/duke-street-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "duke-street-bio" ;
  schema:name "Duke Street Bio"@en ;
  schema:alternateName "Duke Street Bio Ltd"@en ;
  schema:description "Duke Street Bio makes DSB2455, a tablet drug that blocks PARP1, a DNA repair enzyme some cancers rely on, while sparing a related enzyme linked to blood-count side effects. It is in an early trial for advanced cancers with DNA repair defects, including cancer that has spread to the brain."@en ;
  schema:url <https://onco.cc/companies/duke-street-bio/>, <https://dukestbio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://dukestbio.com/>, <https://dukestbio.com/news/>, <https://clinicaltrials.gov/study/NCT06458712> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/secondary-brain-tumours/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/synthetic-lethality-approaches/> ;
  onco:targets <https://onco.cc/targets/parp/> ;
  onco:trials <https://onco.cc/trials/nct06458712/> .